Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):30-5. doi: 10.1097/QAI.0000000000000400.

Risk of breast cancer with CXCR4-using HIV defined by V3 loop sequencing.

Author information

1
*Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD; †British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; ‡Monogram Biosciences, South San Francisco, CA; §Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; ‖Maimonides Medical Center and State University of New York Health Sciences Center at Brooklyn, New York, NY; ¶Georgetown University School of Medicine, Washington, DC; #City of Hope National Medical Center, Duarte, CA; **Keck School of Medicine, University of Southern California, Los Angeles, CA; ††Departments of Medicine, Stroger Hospital and Rush University, Chicago, IL; ‡‡Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; §§Department of Physiological Nursing; and ‖‖The Institute for Human Genetics, University of California, San Francisco, CA; and Departments of ¶¶Clinical Pharmacy; and ##Medicine, University of California, San Francisco, CA.

Abstract

OBJECTIVE:

Evaluate the risk of female breast cancer associated with HIV-CXCR4 (X4) tropism as determined by various genotypic measures.

METHODS:

A breast cancer case-control study, with pairwise comparisons of tropism determination methods, was conducted. From the Women's Interagency HIV Study repository, one stored plasma specimen was selected from 25 HIV-infected cases near the breast cancer diagnosis date and 75 HIV-infected control women matched for age and calendar date. HIV-gp120 V3 sequences were derived by Sanger population sequencing (PS) and 454-pyro deep sequencing (DS). Sequencing-based HIV-X4 tropism was defined using the geno2pheno algorithm, with both high-stringency DS [false-positive rate (3.5) and 2% X4 cutoff], and lower stringency DS (false-positive rate, 5.75 and 15% X4 cutoff). Concordance of tropism results by PS, DS, and previously performed phenotyping was assessed with kappa (κ) statistics. Case-control comparisons used exact P values and conditional logistic regression.

RESULTS:

In 74 women (19 cases, 55 controls) with complete results, prevalence of HIV-X4 by PS was 5% in cases vs 29% in controls (P = 0.06; odds ratio, 0.14; confidence interval: 0.003 to 1.03). Smaller case-control prevalence differences were found with high-stringency DS (21% vs 36%, P = 0.32), lower stringency DS (16% vs 35%, P = 0.18), and phenotyping (11% vs 31%, P = 0.10). HIV-X4 tropism concordance was best between PS and lower stringency DS (93%, κ = 0.83). Other pairwise concordances were 82%-92% (κ = 0.56-0.81). Concordance was similar among cases and controls.

CONCLUSIONS:

HIV-X4 defined by population sequencing (PS) had good agreement with lower stringency DS and was significantly associated with lower odds of breast cancer.

PMID:
25321183
PMCID:
PMC4262599
DOI:
10.1097/QAI.0000000000000400
[Indexed for MEDLINE]
Free PMC Article

Publication type, MeSH terms, Substances, Grant support

Publication type

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center